$AIFF

FIREFLY NEUROSCIENCE, INC.

Firefly Neuroscience develops the Firefly Platform, which combines EEG and ERP acquisition hardware, cloud-based analytics, and a proprietary data repository to provide clinicians with structured reports for brain health assessment and clinical decision-making. Its Evoke System captures brain activity and heart rate variability in clinical settings, and its analytics compare patient data with a reference dataset. The platform supports assessment of cognitive functions and is used by clinicians treating neurological and psychiatric conditions. Firefly sells platform access through subscriptions to clinics, with monthly fees covering the Evoke System, a set volume of assessments, and analytics and reporting; additional scans incur per-scan fees. It also works with pharmaceutical companies and academic research institutions on EEG and ERP analytics for neuroscience drug development and clinical trials. As of December 31, 2025, the Evoke System is in use at more than 85 clinical sites in the United States. Firefly is headquartered in Kenmore, New York.

2
0
0

No SEC Form 4 filings for $AIFF in the last 30 days.

See all $AIFF insider activity →
Low

Firefly Reports 373% Increase In Pediatric ADHD Scan Volume As Platform Adotoption Grows

Firefly Neuroscience (AIFF) reported a 373% year-over-year increase in pediatric ADHD scans using its Evoke platform. The company attributes this growth to broader adoption across neuropsychiatric practices. Firefly also highlighted a partnership with NeuroSigma to offer the Monarch eTNS System, an FDA-cleared treatment for pediatric ADHD. AIFF's stock traded between $0.62 and $3.15 over the past year, closing Monday at $0.88.

Firefly Neuroscience 3Q 2026: Revenue $647K, EPS ($0.07) — 10-Q Summary

Firefly Neuroscience reported 3Q 2026 revenue of $647K, up 67% YoY, with net loss narrowing to $1.48M. Growth was driven by recurring subscription revenue, while gross margin improved to 81%. Operating expenses decreased, including selling and marketing costs down 27%. The Evoke EEG System is in use at 85+ U.S. clinical sites.

Firefly Neuroscience updates brain-computer interface strategy

Firefly Neuroscience (AIFF) updated its brain-computer interface strategy, highlighting its Versus platform. The company has shipped 3,000 Versus headsets, which use wireless EEG technology for brainwave activity tracking in simulations. Firefly aims to leverage this data for AI applications and brain health. The Versus platform generates commercial revenue while the company pursues BCI and AI development. AIFF's Evoke System is FDA-cleared for diagnostic and treatment monitoring.

AIFF sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 2 news stories mentioning AIFF (FIREFLY NEUROSCIENCE, INC.). Coverage has skewed bullish: 2 bullish, 0 neutral, and 0 bearish.

Recent AIFF coverage spans technology, corporate actions and market movers.

What's driving AIFF

AlphAI scores every news story that mentions AIFF with an AI model for sentiment and relevance, and aggregates insider trades from FIREFLY NEUROSCIENCE, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $AIFF

Score

Firefly Reports 373% Increase In Pediatric ADHD Scan Volume As Platform Adotoption Grows

Firefly Neuroscience (AIFF) reported a 373% year-over-year increase in pediatric ADHD scans using its Evoke platform. The company attributes this growth to broader adoption across neuropsychiatric practices. Firefly also highlighted a partnership with NeuroSigma to offer the Monarch eTNS System, an FDA-cleared treatment for pediatric ADHD. AIFF's stock traded between $0.62 and $3.15 over the past year, closing Monday at $0.88.

Firefly Neuroscience updates brain-computer interface strategy

Firefly Neuroscience (AIFF) updated its brain-computer interface strategy, highlighting its Versus platform. The company has shipped 3,000 Versus headsets, which use wireless EEG technology for brainwave activity tracking in simulations. Firefly aims to leverage this data for AI applications and brain health. The Versus platform generates commercial revenue while the company pursues BCI and AI development. AIFF's Evoke System is FDA-cleared for diagnostic and treatment monitoring.

Firefly Hikes on Partnering with NeuroSigma

Firefly Neuroscience (AIFF) and NeuroSigma partnered to promote NeuroSigma's Monarch eTNS System, a non-drug ADHD treatment, through Firefly's Evoke platform network. AIFF shares rose 38.9% to $1.65. According to a 2024 study, 7.1 million U.S. children have ADHD, with many seeking non-medication treatments.

Biotech Stocks In Focus: Aethlon, Tiziana, Capricor, Firefly & Clearmind

Aethlon Medical (AEMD) surged 360% after announcing a merger with North Immunology and a $180M private placement. Tiziana Life Sciences (TLSA) rose 22% due to a clinical trial collaboration. Capricor Therapeutics (CAPR) gained 9% with upcoming Duchenne data. Firefly Neuroscience (AIFF) climbed 26% after a brain-medicine partnership. Clearmind Medicine (CMND) increased 6% following an FDA psychedelic hearing.

$AIFFLowExec change· terminated

FIREFLY NEUROSCIENCE, INC. (AIFF): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

FIREFLY NEUROSCIENCE, INC. (AIFF) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On September 8, 2026, the board of directors (the “Board”) of Firefly Neuroscience, Inc., a Delaware corporation (the “Comp

$AIFFLowShareholder vote

FIREFLY NEUROSCIENCE, INC. (AIFF): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

FIREFLY NEUROSCIENCE, INC. (AIFF) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On August 5, 2026, at the 2026 annual meeting of stockholders (the “ Annual Meeting ”) of Firefly Neuroscience, Inc., a Del

Firefly Neuroscience, Inc.: Firefly Neuroscience (NASDAQ: AIFF) Reports 291% Increase in TMS Center Customer Brain Scan Volumes

Firefly Neuroscience (NASDAQ: AIFF) said TMS center customer clinical assessments using its FDA 510(k)-cleared AI-powered EEG/ERP platform Evoke rose about 291% year over year, nearly four-fold. The company said Evoke combines qEEG and ERP to support clinician assessment of conditions including depression, anxiety, and ADHD, including monitoring before, during, and after TMS.

$AIFFMedOffering· $1M · terminated

FIREFLY NEUROSCIENCE, INC. (AIFF): Termination of a Material Definitive Agreement

FIREFLY NEUROSCIENCE, INC. (AIFF) filed an SEC Form 8-K — Termination of a Material Definitive Agreement. false 0000803578 0000803578 2026-06-25 2026-06-25 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Repor

Related tickers